Opportunity Information: Apply for RFA AI 16 022

  • The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Human Tissue Models for Infectious Diseases (U19)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855, 93.856,.
  • This funding opportunity was created on Apr 07, 2016 and posted on Apr 07, 2016.
  • Applicants must submit their applications by Jul 06, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
  • The number of recipients for this funding is limited to 4 candidate(s).
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
Apply for RFA AI 16 022

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Opportunity Summary:

The Human Tissue Models for Infectious Diseases (U19) funding opportunity (RFA-AI-16-022) is a National Institutes of Health program under HHS (specifically NIH, with the activity rooted in infectious disease research). It is designed to support the creation of a small number of multidisciplinary research Centers that can build and validate advanced in vitro human tissue models to study infectious diseases. The central aim is to push beyond traditional lab systems by developing human-relevant tissue platforms that better reproduce how infections actually unfold in the body, with the expectation that these models will strengthen both basic discovery science and translational work that can inform real-world countermeasures.

This FOA uses the cooperative agreement mechanism (U19), which typically means the funded projects are not just standard investigator-initiated grants but involve substantial scientific and/or programmatic involvement from the NIH. In practice, that usually translates into closer coordination with the funding agency, shared milestones or goals, and an emphasis on producing resources, data, or capabilities that are broadly useful to the infectious disease research community. The “Center” structure also signals that applicants are expected to bring together multiple disciplines and capabilities, for example tissue engineering, cell biology, immunology, microbiology/virology, bioengineering, imaging, computational analysis, and translational expertise, all integrated around building functional tissue models that can be used to study pathogen-host interactions.

The scientific focus is specifically on innovative in vitro human tissue models. These are laboratory-built systems intended to mimic key features of human tissues (such as epithelial barriers, vascular interfaces, immune components, or organ-specific microenvironments) that are important for infection biology. The models supported under this program are meant to serve infectious disease research needs, which commonly include understanding entry and spread of pathogens, host immune responses, tissue damage mechanisms, persistence or latency, and the ways pathogens exploit human tissue architecture. Because the FOA emphasizes both basic and translational research, the intended end uses are broad: generating fundamental mechanistic insights while also enabling more predictive testing of therapeutics, vaccines, or other interventions in a controlled human-relevant setting.

In terms of who can apply, eligibility is wide and includes many types of organizations: public and state-controlled institutions of higher education, private universities, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including those other than small businesses), small businesses, and multiple levels of government entities (state, county, city/township, special districts), as well as Native American tribal governments and tribal organizations, and public housing authorities/Indian housing authorities. This wide eligibility aligns with the multidisciplinary, platform-building nature of the program, where strong teams might include academic labs, medical schools, hospitals, engineering groups, and industry partners that can contribute specialized model development, manufacturing, assay development, or validation expertise.

The program was posted and created on April 7, 2016, with an application closing date of July 6, 2016 (the original and current closing date are the same). The FOA lists an award ceiling of $1,000,000 and anticipates making about 4 awards. Taken together, that suggests a relatively competitive opportunity aimed at supporting a small number of substantial Center-style efforts, each expected to develop high-impact tissue model capabilities rather than a single narrow experiment. The activity category is Health, and the CFDA numbers associated with the opportunity are 93.855 and 93.856, which correspond to NIH programs in allergy, immunology, and infectious diseases and related translational research areas.

Overall, this opportunity is best understood as NIH’s targeted investment in next-generation human tissue modeling for infectious diseases, with the goal of producing in vitro systems that capture human biology more accurately than many existing models. By funding multidisciplinary Centers under a cooperative agreement, the FOA aims to create robust, reusable platforms that can accelerate understanding of infection mechanisms and improve the pipeline for testing interventions in systems that are more predictive of human outcomes.

Frequently Asked Questions (FAQs)

What is the Human Tissue Models for Infectious Diseases (U19) funding opportunity?

This opportunity (RFA-AI-16-022) is an NIH program under HHS that supports the creation of a small number of multidisciplinary research Centers to build and validate advanced in vitro human tissue models for studying infectious diseases.

Which agency is offering this funding opportunity?

The opportunity is offered by the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), and it is rooted in infectious disease research.

What is the main goal of this FOA?

The central goal is to push beyond traditional laboratory systems by developing human-relevant in vitro tissue platforms that more accurately reproduce how infections unfold in the human body, strengthening both basic discovery science and translational research that can inform real-world countermeasures.

What type of funding mechanism is used?

This FOA uses a cooperative agreement mechanism (U19), meaning NIH is expected to have substantial scientific and/or programmatic involvement in the funded projects compared to standard investigator-initiated grants.

What does a U19 cooperative agreement typically imply for awardees?

Based on the description provided, it typically implies closer coordination with NIH, potentially shared milestones or goals, and an emphasis on producing resources, data, or capabilities that are broadly useful to the infectious disease research community.

What does the FOA mean by a “Center”?

The “Center” structure indicates that applicants are expected to build a multidisciplinary effort integrating multiple capabilities around the development and validation of functional human tissue models for infectious disease research.

What kinds of disciplines are expected to be part of a Center team?

Examples mentioned include tissue engineering, cell biology, immunology, microbiology/virology, bioengineering, imaging, computational analysis, and translational expertise, organized around building and using functional tissue models to study pathogen-host interactions.

What types of models are being supported?

The scientific focus is on innovative in vitro human tissue models: laboratory-built systems designed to mimic key features of human tissues that matter for infection biology.

What human tissue features should these models aim to reproduce?

Examples provided include epithelial barriers, vascular interfaces, immune components, and organ-specific microenvironments that are important for understanding infectious disease processes.

What research questions can these tissue models help address in infectious diseases?

The FOA highlights infectious disease research needs such as understanding pathogen entry and spread, host immune responses, tissue damage mechanisms, persistence or latency, and how pathogens exploit human tissue architecture.

Is the program focused on basic research, translational research, or both?

Both. The FOA emphasizes basic and translational research, aiming to enable fundamental mechanistic insights and more predictive testing of interventions in controlled, human-relevant systems.

How might the developed models be used for real-world applications?

The models are intended to support more predictive testing of therapeutics, vaccines, or other interventions in a controlled setting that is more representative of human biology than many existing models.

Who is eligible to apply?

Eligibility is broad and includes public and state-controlled institutions of higher education, private universities, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including those other than small businesses), small businesses, and government entities at multiple levels.

Are tribal entities eligible to apply?

Yes. Native American tribal governments and tribal organizations are listed as eligible applicants.

Are local government or public housing authorities eligible?

Yes. Eligible entities include state, county, city/township, and special district governments, as well as public housing authorities/Indian housing authorities.

Does the FOA encourage multidisciplinary partnerships across sectors?

The wide eligibility aligns with the multidisciplinary, platform-building nature of the program, where teams may include academic labs, medical schools, hospitals, engineering groups, and industry partners contributing specialized development and validation expertise.

When was this funding opportunity posted?

It was posted and created on April 7, 2016.

What is the application due date?

The application closing date is July 6, 2016 (the original and current closing date are the same).

What is the award ceiling?

The FOA lists an award ceiling of $1,000,000.

How many awards does NIH anticipate making?

NIH anticipates making about 4 awards.

What does the expected number of awards suggest about competitiveness?

With about 4 anticipated awards and a focus on Center-style efforts, the opportunity appears relatively competitive and targeted toward a small number of substantial projects expected to produce high-impact tissue model capabilities.

What is the activity category for this opportunity?

The activity category is Health.

Which CFDA numbers are associated with this FOA?

The CFDA numbers listed are 93.855 and 93.856, corresponding to NIH programs in allergy, immunology, and infectious diseases and related translational research areas.

What is the overall purpose of NIH’s investment in this area?

This FOA represents a targeted NIH investment in next-generation human tissue modeling for infectious diseases to produce robust, reusable in vitro platforms that capture human biology more accurately and help accelerate both understanding of infection mechanisms and testing of interventions in more predictive systems.

Browse more business programs for Infectious Disease Research

Browse more opportunities from the same agency: HHS-NIH11

Browse more opportunities from the same category: Health

Next opportunity: Aquatic Invasive Species Cooperative Agreement for the Fiscal Year 2015 Great Lakes Restoration Initiative

Previous opportunity: Cooperative Ecosystem Studies Unit, Californian CESU

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AI 16 022

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AI 16 022) also looked into and applied for these:

Funding Opportunity
Noise-Induced Cochlear Synaptopathy: Basic Studies Informing Potential Therapies (R01) Apply for PAR 16 170

Funding Number: PAR 16 170
Agency: HHS-NIH11
Category: Health
Funding Amount: $500,000
Innovation for HIV Vaccine Discovery (R01) Apply for PAR 16 171

Funding Number: PAR 16 171
Agency: HHS-NIH11
Category: Health
Funding Amount: Case Dependent
Limited Competition: IDeA (Institutional Development Award) Core Optimization (Admin Supp) Apply for PA 16 172

Funding Number: PA 16 172
Agency: HHS-NIH11
Category: Health
Funding Amount: $350,000
Research Partnerships for Scaling Up Mental Health Interventions in Low-and Middle-Income Countries (U19) Apply for PAR 16 174

Funding Number: PAR 16 174
Agency: HHS-NIH11
Category: Health
Funding Amount: $500,000
Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Apply for CDC RFA TS15 150102CONT16

Funding Number: CDC RFA TS15 150102CONT16
Agency: HHS-CDC
Category: Health
Funding Amount: Case Dependent
Resiliency in Communities After Stress and Trauma (Short Title: ReCAST Program) Apply for SM 16 012

Funding Number: SM 16 012
Agency: HHS-SAMHS
Category: Health
Funding Amount: $1,000,000
ResPECT Data Anaysis Apply for EP IDS 16 002

Funding Number: EP IDS 16 002
Agency: HHS-OS-ASPR
Category: Health
Funding Amount: $386,500
Limited Competition: Tissue Chips for Rare Diseases (Admin Supp) Apply for PA 16 173

Funding Number: PA 16 173
Agency: HHS-NIH11
Category: Health
Funding Amount: $100,000
Limited Competition: Tissue Chips and Missing Organs (Admin Supp) Apply for PA 16 178

Funding Number: PA 16 178
Agency: HHS-NIH11
Category: Health
Funding Amount: $50,000
Minority AIDS Initiative Continuum of Care Pilot (MAI-CoC) Syringe Services Programs (SSPs) (Short Title: MAI-CoC: SSP) Apply for SP 16 008

Funding Number: SP 16 008
Agency: HHS-SAMHS
Category: Health
Funding Amount: $82,500
TRANSFORM/WASH Apply for RFA 663 16 000007

Funding Number: RFA 663 16 000007
Agency: USAID-ETH
Category: Health
Funding Amount: $24,000,000
Tribal Management Grant Program Apply for HHS 2016 IHS TMD 0001

Funding Number: HHS 2016 IHS TMD 0001
Agency: HHS-IHS
Category: Health
Funding Amount: $100,000
Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R41/R42) Apply for PA 16 181

Funding Number: PA 16 181
Agency: HHS-NIH11
Category: Health
Funding Amount: Case Dependent
Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R43/R44) Apply for PA 16 180

Funding Number: PA 16 180
Agency: HHS-NIH11
Category: Health
Funding Amount: Case Dependent
Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18) Apply for PAR 16 179

Funding Number: PAR 16 179
Agency: HHS-NIH11
Category: Health
Funding Amount: Case Dependent
Strategies for the Improvement of HIV Envelope Protein Expression and Yield (R41/R42) Apply for PA 16 182

Funding Number: PA 16 182
Agency: HHS-NIH11
Category: Health
Funding Amount: Case Dependent
Products to Support Applied Research Towards Zero Suicide Healthcare Systems (R43/R44) Apply for PAR 16 185

Funding Number: PAR 16 185
Agency: HHS-NIH11
Category: Health
Funding Amount: Case Dependent
Strategies for the Improvement of HIV Envelope Protein Expression and Yield (R43/R44) Apply for PA 16 184

Funding Number: PA 16 184
Agency: HHS-NIH11
Category: Health
Funding Amount: Case Dependent
The USAID Global Health Challenge BAA Apply for BAA GLOBAL HEALTH 2016

Funding Number: BAA GLOBAL HEALTH 2016
Agency: USAID
Category: Health
Funding Amount: Case Dependent
Implementing Public Health Programs and Strengthening Public Health Capacity in Guatemala and Central American Apply for CDC RFA GH13 130604CONT16

Funding Number: CDC RFA GH13 130604CONT16
Agency: HHS-CDC
Category: Health
Funding Amount: Case Dependent

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

USGrants.org applicant portal membership

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 16 022", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.